Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide
Recruitment status was Recruiting
Glibenclamide is metabolized by the hepatic enzyme P450 CYP2C9 to less active form. Polymorphism of this enzyme demonstrated clinical significance when examined on other drugs from the sulfonylurea drug family, to whom Glibenclamide is included.
The investigators assumption is that patients with less active alleles of the enzyme may show lower dose requirements of the drug for glycemic control, when compared to patients homozygotes to wild-type alleles.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
- HbA1c [ Time Frame: 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||October 2009|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01242137
|Contact: Amit Tirosh, Dremail@example.com|
|Assaf Harofe Medical Center||Recruiting|
|Beer Yakov, Israel|
|Contact: Amit Tirosh, Dr 972-52-4748989 firstname.lastname@example.org|
|Principal Investigator: Amit Tirosh, Dr|